Amylyx Pharmaceuticals：Pipeline
Pipeline
Wearecommittedtoexploringthefullpotentialofourexistingandexploratorytherapiesandadvancingourpipelineinanefforttosupportourmissionofone ...。其他文章還包含有：「AmylyxPharmaceuticals」、「Amylyx完成1.35億美元C輪募資，持續研發神經退化性疾病...」、「Careers」、「Investors」、「LeadershipTeam」、「News」、「OurCompany」、「PressReleases-Investors」
查看更多 離開網站
Amylyx Pharmaceuticals
https://www.amylyx.com
Everything we do at Amylyx is centered around those living with neurodegenerative diseases. We are on a mission to discover and develop treatments for ...
Amylyx 完成1.35 億美元C 輪募資，持續研發神經退化性疾病 ...
https://geneonline.news
FDA 核准ALS 療法進度遲緩. 2017 年，脊髓側索硬化症藥物AMX0035 便取得FDA 認可的孤兒藥資格（Orphan Drug Desigantion），但此後核准進度 ...
Careers
https://www.amylyx.com
We are looking for mission-driven builders, thought-provokers, disruptors, audacious minds, and compassionate souls. Most of all, we're looking for the ones who ...
Investors
https://investors.amylyx.com
The Investor Relations website contains information about Amylyx Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial ...
Leadership Team
https://www.amylyx.com
Executive team · Debra Canner · Josh Cohen · James M. Frates · Tom Holmes · Justin Klee · Gina M. Mazzariello · Margaret Olinger · Patrick Yeramian, MD, MBA.
News
https://www.amylyx.com
From clinical trials to corporate announcements, we're proud to share our recent updates and progress with the community.
Our Company
https://www.amylyx.com
Amylyx is a global pharmaceutical company based in Cambridge, Massachusetts, that is dedicated to the discovery and development of potential treatments for ...
Press Releases - Investors
https://investors.amylyx.com
Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference ... Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 ...